Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2017

Open Access 01-12-2017 | Research article

Early response in cognitive-behavior therapy for syndromes of medically unexplained symptoms

Authors: Maria Kleinstäuber, Michael J. Lambert, Wolfgang Hiller

Published in: BMC Psychiatry | Issue 1/2017

Login to get access

Abstract

Background

Early dramatic treatment response suggests a subset of patients who respond to treatment before most of it has been offered. These early responders tend to be over represented among those who are well at termination and at follow-up. Early response patterns in psychotherapy have been investigated only for a few of mental disorders so far. The main aim of the current study was to examine early response after five therapy-preparing sessions of a cognitive behavior therapy (CBT) for syndromes of medically unexplained symptoms (MUS).

Methods

In the context of a randomized, waiting-list controlled trial 48 patients who suffered from ≥3 MUS over ≥6 months received 5 therapy-preparing sessions and 20 sessions of CBT for somatoform disorders. They completed self-report scales of somatic symptom severity (SOMS-7 T), depression (BDI-II), anxiety (BSI), illness anxiety and behavior (IAS) at pre-treatment, after 5 therapy-preparing sessions (FU-5P) and at therapy termination (FU-20 T).

Results

The current analyses are based on data from the treatment arm only. Repeated measure ANOVAs revealed a significant decrease of depression (d = 0.34), anxiety (d = 0.60), illness anxiety (d = 0.38) and illness behavior (d = 0.42), but no change of somatic symptom severity (d = −0.03) between pre-treatment and FU-5P. Hierarchical linear multiple regression analyses showed that symptom improvements between pre-treatment and FU-5P predict a better outcome at therapy termination for depression and illness anxiety, after controlling for pre-treatment scores. Mixed-effect ANOVAs revealed significant group*time interaction effects indicating differences in the course of symptom improvement over the therapy between patients who fulfilled a reliable change (i.e., early response) during the 5 therapy-preparing sessions and patients who did not reach an early reliable change. Demographic or clinical variables at pre-treatment were not significantly correlated with differential scores between pre-treatment and FU-5P (−.23 ≤ r ≤ .23).

Conclusions

Due to several limitations (e.g., small sample size, lack of a control group) the results of this study have to be interpreted cautiously. Our findings show that reliable changes in regard to affective-cognitive and behavioral variables can take place very early in CBT of patients with distressing MUS. These early changes seem to be predictive of the outcome at therapy termination. Future studies are needed in order to replicate our results, and to identify mechanisms of these early response patterns in somatoform patients.

Trial registration

ISRCTN. ISRCTN17188363. Registered retrospectively on 29 March 2007.
Literature
1.
Nierenberg AA, Quitkin FM, Kremer C, Keller MB, Thase ME. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology. 2004;29:1012–8.CrossRefPubMed
2.
Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, Mcgrath PJ, Harrison W. Use of pattern-analysis to identify true drug response - a replication. Arch Gen Psych. 1987;44:259–64.CrossRef
3.
Stewart JW, Tricamo E, McGrath PJ, Quitkin FM. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Am J Psychiat. 1997;154:31–6.CrossRefPubMed
4.
Fennell MJV, Teasdale JD. Cognitive therapy for depression - individual differences and the process of change. Cognitive Ther Res. 1987;11:253–71.CrossRef
5.
Renaud J, Brent DA, Baugher M, Birmaher B, Kolko DJ, Bridge J. Rapid response to psychosocial treatment for adolescent depression: a two-year follow-up. J Am Acad Child Psy. 1998;37:1184–90.CrossRef
6.
Haas E, Hill RD, Lambert MJ, Morrell B. Do early responders to psychotherapy maintain treatment gains? J Clin Psychol. 2002;58:1157–72.CrossRefPubMed
7.
Lutz W, Stulz N, Köck K. Patterns of early change and their relationship to outcome and follow-up among patients with major depressive disorders. J Affect Disorders. 2009;118:60–8.CrossRefPubMed
8.
Lutz W, Stulz N, Smart DW, Lambert MJ. Patterns of early change in outpatient therapy [Die Identifikation früher Veränderungsmuster in der ambulanten Psychotherapie]. Z Kl Psych Psychoth. 2007;36:93–104.CrossRef
9.
Sharpe M, Mayou R, Bass C: Concepts, theories and terminology. In Treatment of functional somatic symptoms. Edited by Mayou R, Bass C, Sharpe M. Oxford, UK: Oxford University Press; 1995: 3–16.
10.
American Psychiatric Association: Diagnostic and statistical manual for mental disorders. Fourth edition, text revision. Washington, DC: American Psychiatric Press; 2000.
11.
American Psychiatric Association: Diagnostic and statistical manual of mental disorders. Fifth edition. DSM-5. Washington, DC: APA; 2013.
12.
Jacobi F, Wittchen HU, Holting C, Hofler M, Pfister H, Muller N, Lieb R. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German health interview and examination survey (GHS). Psychol Med. 2004;34:597–611.CrossRefPubMed
13.
Steinbrecher N, Körber S, Frieser D, Hiller W. The prevalence of medically unexplained symptoms in primary care. Psychosomatics. 2011;52:263–71.CrossRefPubMed
14.
Nimnuan C, Hotopf M, Wessely S. Medically unexplained symptoms: an epidemiological study in seven specialities. J Psychosom Res. 2001;51:361–7.CrossRefPubMed
15.
Rief W, Rojas G. Stability of somatoform symptoms - implications for classification. Psychosom Med. 2007;69:864–9.CrossRefPubMed
16.
van Eck van der Sluijs JV, Ten Have M, Rijnders C, van Marwijk H, de Graaf R, van der Feltz-Cornelis C: Medically unexplained and explained physical symptoms in the general population: Association with prevalent and incident mental disorders. PLoS One 2015, 10.
17.
de Waal MW, Arnold IA, Eekhof JA, van Hemert AM. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Brit J Psychiat. 2004;184:470–6.CrossRefPubMed
18.
Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psych. 2005;62:903–10.CrossRef
19.
Van Dessel N, Den Boeft M, Van der Wouden JC, Kleinstäuber M, Leone SS, Terluin B, Numans ME, Van der Horst HE, Van Marwijk H: Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD011142. http://​dx.​doi.​org/​10.​1002/​14651858.​CD011142.​pub2.
20.
Kleinstäuber M, Witthöft M, Hiller W. Efficacy of short-term psychotherapy for multiple medically unexplained physical symptoms: a meta-analysis. Clin Psychol Rev. 2011;31:146–60.CrossRefPubMed
21.
Martin A, Korn HJ, Cebulla M, Saly M, Fichter MM, Hiller W. Causal attributions about bodily sensations in somatoform disorders. Z Psychiatr Psych Ps. 2007;55:31–41.
22.
Murray AM, Toussaint A, Althaus A, Löwe B. The challenge of diagnosing non-specific, functional, and somatoform disorders: a systematic review of barriers to diagnosis in primary care. J Psychosom Res. 2016;80:1–10.CrossRefPubMed
23.
Wileman L, May C, Chew-Graham CA. Medically unexplained symptoms and the problem of power in the primary care consultation: a qualitative study. Fam Pract. 2002;19:178–82.CrossRefPubMed
24.
Ring A, Dowrick C, Humphris G, Salmon P. Do patients with unexplained physical symptoms pressurise general practitioners for somatic treatment? A qualitative study. Brit Med J. 2004;328:1057–60.CrossRefPubMedPubMedCentral
25.
Salmon P, Humphris GM, Ring A, Davies JC, Dowrick CF. Primary care consultations about medically unexplained symptoms: patient presentations and doctor responses that influence the probability of somatic intervention. Psychosom Med. 2007;69:571–7.CrossRefPubMed
26.
McGorm K, Burton C, Weller D, Murray G, Sharpe M. Patients repeatedly referred to secondary care with symptoms unexplained by organic disease: prevalence, characteristics and referral pattern. Fam Pract. 2010;27:479–86.CrossRefPubMed
27.
Lackner JM, Gudleski GD, Krasner SS, Powell C, Katz LA. Rapid response to cognitive behavior therapy for irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008;8:426–32.CrossRef
28.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395–402.CrossRefPubMed
29.
Ilardi SS, Craighead WE. The role of non-specific factors in cognitive-behavior for depression. Clin Psychol-Sci Pr. 1994;1:138–56.CrossRef
30.
Ilardi SS, Craighead WE. Rapid early response, cognitive modification, and nonspecific factors in cognitive behavior therapy for depression: a reply to tang and DeRubeis. Clin Psychol-Sci Pr. 1999;6:295–9.CrossRef
31.
Janca A, Hiller W. ICD-10 checklists - a tool for clinicians' use of the ICD-10 classification of mental and behavioral disorders. Compr Psychiatry. 1996;37:180–7.CrossRefPubMed
32.
Mewes R, Rief W, Stenzel N, Glaesmer H, Martin A, Brahler E. What is "normal" disability? An investigation of disability in the general population. Pain. 2009;142:36–41.CrossRefPubMed
33.
Faul F, Erdfelder E, Lang AG, Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.CrossRefPubMed
34.
First MB, Gibbon M, Spitzer RL, Williams JBW, Smith Benjamin L. User's guide for the structured clinical interview for DSM-IV Axis II personality disorders (SCID-II). Washington DC: American Psychiatric Press; 1997.
35.
Kleinstäuber M, Thomas P, Witthöft M, Hiller W. Cognitive-behavioral therapy for medically unexplained physical symptoms and somatoform disorders [Kognitive Verhaltenstherapie bei medizinisch unerklärten Körperbeschwerden und somatoformen Störungen]. Berlin, Germany: Springer; 2012.CrossRef
36.
Rief W, Hiller W. A new approach to the assessment of the treatment effects of somatoform disorders. Psychosomatics. 2003;44:492–8.CrossRefPubMed
37.
World Health Organization: International statistical classification of diseases. 10th revision (ICD-10). Genf, Switzerland: WHO; 1996.
38.
Beck AT, Steer RA, Brown GK. Beck depression Inventory II (BDI-II). Manual. San Antonio, TX: Psychological Corporation; 1996.
39.
Derogatis LR. The Brief symptom Inventory (BSI): administration, scoring, and procedures manual II. Baltimore, MD: Clinical Psychometric Research; 1992.
40.
Boulet J, Boss MW. Reliability and validity of the Brief symptom Inventory. Psychol Assessment. 1991;3:433–7.CrossRef
41.
Kellner R. Abridged manual of the illness Attitude scales. Albuquerque, NM: University of New Mexico, Department of Psychiatry, School of Medicine, Mimeographed; 1987.
42.
Speckens AEM, Spinhoven P, Sloekers PPA. Bolk JH, vanHemert AM: a validation study of the whitely index, the illness Attitude scales, and the somatosensory amplification scale in general medical and general practice patients. J Psychosom Res. 1996;40:95–104.CrossRefPubMed
43.
Hiller W, Rief W, Fichter MM. Dimensional and categorical approaches to hypochondriasis. Psychol Med. 2002;32:707–18.CrossRefPubMed
44.
Jacobson NS, Truax P. Clinical-significance - a statistical approach to defining meaningful change in psychotherapy-research. J Consult Clin Psych. 1991;59:12–9.CrossRef
45.
Schafer JL. Analysis of incomplete multivariate data. New York: Chapman & Hall; 2000.
46.
47.
Steketee G, Chambless DL. Methodological issues in prediction of treatment outcome. Clin Psychol Rev. 1992;12:387–400.CrossRef
48.
United Nations Educational Scientific and Cultural Organization Institute for Statistics. International standard classification of education (ISCED 97). Paris (France): United Nations Educational Scientific and Cultural Organization; 2006.
49.
Cuijpers P, van Straten A, Bohlmeijer E, Hollon SD, Andersson G. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychol Med. 2010;40:211–23.CrossRefPubMed
50.
Erekson D, Lambert MJ, Horner J. Different lens or different picture? Psychother Res: Comparing methods of defining dramatic change in psychotherapy; in press.
51.
Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Eur Neuropsychopharmacol. 2010;20:S60–1.CrossRef
52.
Moerman DE. Meaning, medicine and the placebo effect. Cambridge, MA: Cambridge Univ. Press; 2002.CrossRef
53.
Colloca L, Miller FG. Role of expectations in health. Curr OpinPsychiatr. 2011;24:149–55.
54.
Lambert MJ. Early response in psychotherapy: further evidence for the importance of common factors rather than "placebo effects". J Clin Psychol. 2005;61:855–69.CrossRefPubMed
55.
56.
Rief W, Heitmüller AM, Reisberg K, Rüddel H. Why reassurance fails in patients with unexplained symptoms - an experimental investigation of remembered probabilities. PLoS Med. 2006;3:1266–72.CrossRef
57.
Linton SJ, McCracken LM, Vlaeyen JWS. Reassurance: help or hinder in the treatment of pain. Pain. 2008;134:5–8.CrossRefPubMed
58.
Turner H, Bryant-Waugh R, Marshall E. The impact of early symptom change and therapeutic alliance on treatment outcome in cognitive-behavioural therapy for eating disorders. Behav Res Ther. 2015;73:165–9.CrossRefPubMed
59.
60.
Kleinstäuber M, Gottschalk J, Berking M, Rau J, Rief W. Enriching cognitive behavior therapy with emotion regulation training for patients with multiple medically unexplained symptoms (ENCERT): design and implementation of a multicenter, randomized, active-controlled trial. Contemp Clin Trials. 2016;47:54–63.CrossRefPubMed
Metadata
Title
Early response in cognitive-behavior therapy for syndromes of medically unexplained symptoms
Authors
Maria Kleinstäuber
Michael J. Lambert
Wolfgang Hiller
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2017
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-017-1351-x

Other articles of this Issue 1/2017

BMC Psychiatry 1/2017 Go to the issue

Research article

Vocational rehabilitation for adults with psychotic disorders in a Scandinavian welfare society

Research article

The content of delusions in a sample of South African Xhosa people with schizophrenia

Research article

Depression stigma and migration – results of a survey from Germany

Research article

Predictors of long term use of psychiatric services of patients with recent-onset schizophrenia: 12 years follow-up

Research article

Outcomes identified and prioritised by consumers of Partners in Recovery: a consumer-led study

Research article

Qualitative process evaluation of a psycho-educational intervention targeted at people diagnosed with schizophrenia and their primary caregivers in Jordan